⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747322 | 0.85 | — | — | |
| SCHEMBL1718947 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL8815798 | 0.76 | PI4KA (0.42) | — | |
| SCHEMBL23847549 | 0.74 | — | — | |
| SCHEMBL12844337 | 0.74 | — | — | |
| SCHEMBL13495922 | 0.74 | — | — | |
| SCHEMBL18074893 | 0.69 | LRRK2 (0.43) | — | |
| SCHEMBL3679230 | 0.67 | — | — | |
| SCHEMBL783585 | 0.67 | — | — | |
| SCHEMBL13403365 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| CN-1688579-A | Condensed pyridines and pyrimidines with TIE2 (TEK) activity | ASTRAZENECA AB (SE) | 2005-10-26 | — | — | CN | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |